MARKET

SCNLF

SCNLF

Scancell Holdings Plc London
OTCPK
0.145
NaN%
Closed 09:30 01/16 EST
OPEN
--
PREV CLOSE
0.145
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.228
52 WEEK LOW
0.119
MARKET CAP
150.48M
P/E (TTM)
-8.6310
1D
5D
1M
3M
1Y
5Y
1D
Scancell’s iSCIB1+ Shows Promising Results in Melanoma Trial
TipRanks · 12/09/2025 07:17
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
Barchart · 12/09/2025 01:00
Scancell’s iSCIB1+ Shows Promising Results in Melanoma Treatment
TipRanks · 11/07/2025 07:59
Research Update
Barchart · 11/07/2025 01:12
Scancell Holdings Successfully Passes AGM Resolutions
TipRanks · 10/30/2025 15:32
Scancell Holdings Announces AGM and Annual Report Release
TipRanks · 10/03/2025 06:07
Scancell Holdings: Strategic Share Acquisition by Vulpes Testudo Fund
TipRanks · 09/16/2025 06:08
Weekly Report: what happened at SCNLF last week (0908-0912)?
Weekly Report · 09/15/2025 10:13
More
About SCNLF
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

Webull offers Scancell Holdings Plc stock information, including OTCPK: SCNLF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNLF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNLF stock methods without spending real money on the virtual paper trading platform.